Testimonials and Informational Videos on Branded Prescription Drug Websites: Experimental Study to Assess Influence on Consumer Knowledge and Perceptions

Helen W Sullivan¹, PhD, MPH; Amie C O'Donoghue¹, PhD; Jennifer Gard Read², MPH; Jacqueline B Amoozegar², MSPH; Kathryn J Aikin¹, PhD; Douglas J Rupert², MPH

¹US Food and Drug Administration, Silver Spring, MD, United States
²RTI International, Research Triangle Park, NC, United States

Abstract

Background: Direct-to-consumer (DTC) promotion of prescription drugs can affect consumer behaviors and health outcomes, and Internet drug promotion is growing rapidly. Branded drug websites often capitalize on the multimedia capabilities of the Internet by using videos to emphasize drug benefits and characteristics. However, it is unknown how such videos affect consumer processing of drug information.

Objective: This study aimed to examine how videos on prescription drug websites, and the inclusion of risk information in those videos, influence consumer knowledge and perceptions.

Methods: We conducted an experimental study in which online panel participants with acid reflux (n=1070) or high blood pressure (n=1055) were randomly assigned to view 1 of the 10 fictitious prescription drug websites and complete a short questionnaire. On each website, we manipulated the type of video (patient testimonial, mechanism of action animation, or none) and whether the video mentioned drug risks.

Results: Participants who viewed any video were less likely to recognize drug risks presented only in the website text (P≤.01). Including risk information in videos increased participants’ recognition of the risks presented in the videos (P≤.01). However, in some cases, including risk information in videos decreased participants’ recognition of the risks not presented in the videos (ie, risks presented in text only; P≤.04). Participants who viewed a video without drug risk information thought that the website placed more emphasis on benefits, compared with participants who viewed the video with drug risk information (P≤.01). Compared with participants who viewed a video without drug risk information, participants who viewed a video with drug risk information thought that the drug was less effective in the high blood pressure sample (P=.03) and thought that risks were more serious in the acid reflux sample (P=.01). There were no significant differences between risk and nonrisk video conditions on other perception measures (P>.05). In addition, we noted a few differences among the types of videos.

Conclusions: Including risks in branded drug website videos may increase in-video risk retention at the expense of text-only risk retention.

(J Med Internet Res 2018;20(1):e13) doi: 10.2196/jmir.7959

KEYWORDS

Internet; marketing; drug prescriptions; risk
Introduction

Background

Direct-to-consumer (DTC) marketing of prescription drugs is correlated with increases in consumer drug spending, prescription drug use, and prescription requests [1-6]. However, studies have revealed mixed findings as to whether DTC marketing leads to more informed decisions by consumers [7-9]. DTC marketing on the Internet is rapidly growing [10,11] with a 648% increase in spending on Internet promotion between 2001 and 2010 [12]; therefore, it is critical to understand how this medium may affect outcomes related to informed decision making.

Pharmaceutical companies use a number of different Internet activities, most commonly to promote products and communicate with consumers [13]. To this end, most leading pharmaceutical companies maintain two types of websites: websites with corporate business information and websites promoting specific drugs or medications, known as branded drug websites (eg, DrugX.com). Branded drug websites typically provide information about the branded drug, the disease or medical condition, support measures, and ways to locate physicians and pharmacists [14]. Branded drug websites often use videos as a marketing tool to emphasize a promoted drug’s benefits and characteristics [14-18]. These videos may share features with DTC television advertising. For instance, DTC television advertisements frequently include factual information and positive emotional appeals, often in the form of testimonials [19]. However, consumers may react differently to videos in Internet promotion [20]. One way in which videos on websites differ from television advertisements is that these videos are often presented along with text on the website, creating a mix of dynamic and static formats. The movement in the video could increase attention to the video, thereby causing greater recall of the information in the video and perhaps influencing the perceptions of the risks or the benefits. Previous research on the influence of dynamic videos is mixed [21], but a meta-analysis [22] found a small benefit for dynamic versus static images when learning information.

Testimonial Videos

Branded drug websites have sometimes showcased video testimonials of expert medical sources as well as patients who have been treated successfully with the promoted drug [15,16]. Previous research has not examined testimonials within the context of DTC marketing; however, studies in other health-related areas have found mixed evidence about how patient testimonials affect individuals’ perceptions of their disease risk. Some studies have found that testimonials heighten consumer risk perceptions for issues such as human papillomavirus (HPV), human immunodeficiency virus (HIV), and other sexually transmitted diseases [23,24]. However, other studies have found that testimonials did not change consumer risk perceptions on these issues [25]. Trevana and colleagues reviewed 3 articles that used narratives to convey risk information and concluded that patient testimonials should be used with caution because they can have unpredictable effects on risk perceptions [26]. In addition, another study concluded that the use of patient testimonials in decision aids should be avoided until their impact is better understood, because there are concerns that stories have the potential to bias patients’ decisions [27]. Given these mixed findings, we examined the role of video testimonials on branded drug websites, where the understanding of drug risks and benefits is a critical part of an informed discussion with a health care provider.

Informational Videos

Another strategy to promote branded drugs on the Internet is the use of videos that provide information about the product. Although previous studies have examined the presentation of information about topics ranging from astrophysics [28] to pulley systems [21], we are unaware of any study that has examined the presentation of prescription drug information on branded drug websites. DTC promotion is replete with technical information that must be conveyed to adequately represent the benefits and risks of the product, according to US Food and Drug Administration (FDA) regulations [29]. Thus, we examined the presence of a dynamic informational video on the website describing the drug’s mechanism of action to determine whether this presentation influenced viewers’ understanding of the promoted drug’s benefits and risks.

Research Questions

FDA regulations state that prescription drug promotion should include a fair balance of information about the benefits and risks of promoted products, in terms of both content and presentation [29]. The regulations further specify that important risk information should be presented in at least the audio, or in both the audio and visual of broadcast advertisements. All prescription drug promotions should be truthful, balanced, and nonmisleading, regardless of the media in which that promotion occurs [30]. However, questions remain about how best to achieve “fair balance” in Internet DTC promotion [31-34]. The purpose of this study was to examine how videos on prescription drug websites—and the content of those videos—influence consumers’ knowledge, perceptions, and intentions related to the advertised drug.

We had 2 overarching research questions: (1) how does the presence of Web videos (testimonials and informational videos) influence consumer knowledge and perceptions of drugs? and (2) how does including risk information in Web videos influence consumer knowledge and perceptions of drugs? We hypothesized that the presence, versus absence, of Web videos would lead to greater retention of benefit information, and therefore higher drug efficacy perceptions and greater intentions to search for information about the drug. This hypothesis is based on the expectation that video presentations draw attention and that the focus of videos is often benefit information (eg, centered on a patient attesting to the drug effectiveness). Accordingly, we also hypothesized that the presence, versus absence, of Web videos would lead to less retention of the risk information, and therefore lower drug risk perceptions. In addition, we hypothesized that videos including risk information, compared with videos without risk information, would lead to greater retention of the risk information, and therefore higher drug risk perceptions and lower intentions to search for information about the drug. We did not have hypotheses about
potential differences between testimonials and informational videos; however, because we randomly assigned participants
to the type of video they viewed, we tested for any differences
between these conditions. Finally, we explored whether
including a video and whether including risk information in the
video influenced perceptions of the website itself.

Methods

Study Design

We conducted the study with consumers with acid reflux and
consumers with high blood pressure and exposed them to a
mock drug website advertising a fictitious drug (Fentiva or
Plistaz) designed to treat their respective condition. We chose
these medical conditions because they affect a large number of
people and represent both symptomatic (acid reflux) and
asymptomatic (high blood pressure) conditions. We manipulated
the type of video participants viewed and the prominence of the
risk information on the websites. All websites contained the
benefit and risk information in the text. We manipulated whether
the websites presented a video of a personal testimonial, an
informational mechanism of action video, or no video at all
(control group). In the video conditions, we also manipulated
the prominence of the risk information by including some risk
information (high-risk prominence) or by not including some
risk information (low-risk prominence) in the video.
Experimental conditions are presented in Figure 1. To ensure
that our fictitious websites were realistic, we reviewed actual
prescription drug websites and consulted FDA’s Office of
Prescription Drug Promotion. We designed the fictitious
websites to mirror real-life prescription drug websites in
structure (eg, homepage plus 2 subpages), content (eg, drug
benefits and risks and tips for disease management), and design
(eg, consistent banner and heading across all pages and photos
of patients or caregivers). The study was approved by the
relevant institutional review boards.

Participants

The sampling frame was the GfK Custom Research North
America KnowledgePanel, a probability-based online consumer
panel based on a representative random sample of US adults.
Panelists were randomly selected and invited to participate in
the study if they were aged 18 years or older, self-reported to
the panel that they were medically diagnosed with acid reflux
or high blood pressure, did not participate in the study pretest,
were capable of viewing and listening to websites on a desktop
computer or device, had broadband Internet access, and used a
device with Adobe Flash Player software. We randomly assigned
participants to 1 of the 5 experimental arms within each illness
group and confirmed their self-reported medical diagnosis. For
acid reflux, we invited a total of 2226 panelists to participate
in the study. Out of these panelists, 1774 responded and 1070
completed the study. For high blood pressure, we invited a total
of 2020 panelists to participate in the study. Out of these
panelists, 1559 responded and 1055 completed the study. A
summary of participants’ demographic characteristics is
presented in Table 1.

Procedure

After completing the screening questions, participants were
instructed to click a hyperlink to open the study website in a
new window (675x1064 pixels). In addition, participants were
instructed to turn up the volume and watch any videos. Exposure
to the website was forced (ie, participants were not able to
proceed to the questionnaire without clicking the hyperlink and
landing on the website). Each website included a homepage and
2 subpages. Participants were allowed to navigate back and
forth among them without time restrictions. Internet browser
controls were removed from the stimuli window to simplify
navigation.
In all conditions, the website presented both the drug’s risk and
benefit information as text. In the control condition, no video
was present on the website. In the testimonial condition, the
website included a video featuring an actor depicting a patient
who described how the drug worked for them (including treating
acid reflux or lowering blood pressure). In the mechanism of
action video condition, the website included a dynamic animated
video depicting how the drug mechanism treats the illness
(including treating acid reflux or lowering blood pressure). In
the high-risk prominence testimonial condition, the “patient”
stated some of the risk information. In the high-risk prominence
mechanism of action videos, the voiceover stated some of the
risk information while the risks were presented dynamically
through text or icons. The risk information included in the
high-risk prominence conditions was identical in the testimonials
and mechanism of action videos. The website layout is depicted
in Figure 2.
Table 1. Demographic characteristics of the participants.

| Demographic characteristics | Acid reflux sample, weighted (N=1070) n (%) | High blood pressure sample, weighted (N=1055) n (%) |
|-----------------------------|---------------------------------------------|---------------------------------------------------|
| Sex                         |                                             |                                                   |
| Male                        | 449 (41.96)                                 | 505 (47.87)                                       |
| Female                      | 621 (58.04)                                 | 550 (52.13)                                       |
| Age, years                  |                                             |                                                   |
| 18-24                       | 22 (2.06)                                   | 6 (0.57)                                          |
| 25-34                       | 69 (6.45)                                   | 26 (2.46)                                         |
| 35-44                       | 145 (13.55)                                 | 94 (8.91)                                         |
| 45-54                       | 212 (19.81)                                 | 188 (17.82)                                       |
| 55-64                       | 274 (25.61)                                 | 313 (29.67)                                       |
| 65-74                       | 249 (23.27)                                 | 310 (29.38)                                       |
| 75+                         | 99 (9.25)                                   | 118 (11.18)                                       |
| Race or ethnicity a         |                                             |                                                   |
| White                       | 925 (86.45)                                 | 838 (79.43)                                       |
| Black                       | 97 (9.06)                                   | 194 (18.39)                                       |
| Other                       | 105 (9.81)                                  | 80 (7.58)                                         |
| Hispanic                    | 88 (8.22)                                   | 93 (8.82)                                         |
| Education                   |                                             |                                                   |
| Less than high school       | 52 (4.86)                                   | 50 (4.74)                                         |
| High school graduate        | 419 (39.16)                                 | 408 (38.67)                                       |
| Some college                | 315 (29.44)                                 | 305 (28.91)                                       |
| College degree or higher    | 284 (26.54)                                 | 292 (27.68)                                       |

aThere is some overlap between categories as Hispanics are also counted in the 3 race categories.

We programmed the videos to play automatically, thus forcing exposure to the manipulations. No control bar was available; participants could not stop or mute the video once it began playing, although they could close the website whenever they wanted. Participants could replay the video as many times as desired. Once participants closed the stimuli window and continued to the questionnaire, they were unable to view the website again.

Measures

We used Web logs to track participants’ interaction with the fictitious drug websites and translated these logs into navigation variables that could be used to analyze participants’ behavior, including two measures of video exposure: (1) whether participants were fully exposed or partially exposed to the video and (2) whether or not they replayed the video.

We measured risk recall by asking participants to list the risks of the drug in an open-ended text box. For the acid reflux sample, we created a measure of risk recall by coding whether participants reported the risks presented in the video: nausea, headache, stomach pain, diarrhea, constipation, or fractures (0-6). For the high blood pressure sample, we created a measure of risk recall by coding whether participants reported the side effects (diarrhea, rash, or cough) and limitations (that the drug could not be taken if pregnant, used as a salt substitute, used with salt, or used while drinking alcohol) presented in the video (0-7).

To measure risk recognition, we presented participants with two risks that appeared in the video and in the website text, two risks that appeared in the website text only, and four filler statements. Participants indicated whether each statement was mentioned on the website as a risk of taking the drug. For the acid reflux sample, we measured whether they recognized the risks presented in the video [fracture risk (0-1) and nausea risk (0-1)] and the risks presented in the website text only [warnings and precautions regarding special liver tests (0-1) and women who are nursing (0-1)]. Note that although the videos did not include the warning about special liver tests, they did say to tell your doctor if you have liver disease. For the high blood pressure sample, we measured whether they recognized the risks presented in the video [diarrhea risk (0-1) and salt-intake warning (0-1)] and the risks presented in the website text only [fetal risk (0-1) and angioedema warning (0-1)].
We measured benefit recall by asking participants to list the benefits of the drug in an open-ended text box. For the acid reflux sample, we created a measure of benefit recall by coding whether participants reported that the drug could relieve acid reflux [including terms such as heartburn and GERD (gastroesophageal reflux disease); (0-1)]. For the high blood pressure sample, we created a measure of benefit recall by coding whether participants reported that the drug could lower blood pressure (0-1).

To measure benefit recognition, we presented participants with a list of statements about the drug. Participants indicated whether each statement was mentioned on the website as a benefit of taking the drug. For the acid reflux sample, we measured whether the participants recognized the benefit of the drug, “Fentiva can provide relief from heartburn” (0-1). For the high blood pressure sample, we measured whether the participants recognized the benefit of the drug, “Plistaz lowers blood pressure by reducing the amount of renin in the body” (0-1).

Perceived drug risk was measured by 2 items that assessed participants’ thoughts on how many people would have side effects out of 100 people who take the drug (likelihood; open-ended item with values ranging from 0 to 100) and how serious the side effects would be for them (magnitude; 1=not at all serious, 6 = very serious). Perceived drug efficacy was measured by 2 items that assessed participants’ thoughts on how many people would benefit out of 100 people who take the drug (likelihood; open-ended item with values ranging from 0 to 100) and how effective the drug would be for them (magnitude; 1=would help very little to 6=would help a lot).

Perceived balance of drug benefits and risks was measured by asking participants how they would rate the drug on its balance of risks and benefits (1=risks outweigh benefits to 7=benefits outweigh risks).

We measured two types of behavioral intentions: the intention to interact with one’s physician and the intention to seek additional information about the drug on the Internet. For the physician intention measure, we averaged 3 items that assessed how likely participants were to talk to their doctor about the drug, ask their doctor for a sample of the drug, and ask their doctor to prescribe the drug (acid reflux alpha=.94; high blood pressure alpha=.93). For the information-seeking intention measure, we averaged 3 items that assessed how likely participants were to look for information about the drug on medical websites, look for information on the Internet about people’s experience with the drug, and print information from the drug website (acid reflux alpha=.90; high blood pressure alpha=.90). All intention items used the same scale (1=very unlikely to 5=very likely).

We also asked participants about the website itself. We measured website skepticism with the average of 2 items that assessed whether participants thought the information on the websites was true (acid reflux alpha=.66; high blood pressure alpha=.71). Perceived balance of website benefits and risks was measured by asking participants whether they thought the website placed more emphasis on risks or benefits of the drug (1=more emphasis on risks to 7=more emphasis on benefits).
Data Analysis
Weighting was used to account for the underrepresentation of minority groups and other types of sampling and survey errors. We transformed perceived drug efficacy likelihood (by squaring it) and perceived drug risk likelihood (by using the natural log), resulting in approximately normal distribution of the data in the two illness populations. We conducted all hypothesis tests using the transformed variables.

We conducted one-way analysis of variances (ANOVAs) to test the relationship between video type condition (testimonial, mechanism of action, and control) and the risk recall, perception, intention, and skepticism measures. If the effect was significant at P < .05, we performed pairwise comparisons by comparing the testimonial and mechanism of action video type conditions with the control condition, using a Bonferroni-adjusted threshold of P = .025. We conducted two-way ANOVAs to test the relationship between the video type condition (testimonial and mechanism of action) and risk prominence (low and high) and the risk recall, perception, intention, and skepticism measures. We conducted two sets of logistic regressions for risk recognition and benefit recall and retention: one examining the video type conditions compared with the control condition and one examining the main effects and interaction of video type condition and risk prominence.

Results
Video Exposure
Acid Reflux and High Blood Pressure
All participants were exposed to the video, and most of them viewed the entire video (94.8% in the acid reflux sample and 98.6% in the high blood pressure sample). Only a few participants replayed the video (7.5% in the acid reflux sample and 6.8% in the high blood pressure sample).

Retention of Drug Risk Information
Acid Reflux
We tested the effect of risk prominence and video type condition on risk recall. We found that participants in the high-risk prominence condition recalled more risks compared with participants in the low-risk prominence condition (F_{1,860} = 4.00, P = .046, d = .14; Table 2).

We also tested the effect of risk prominence and video type condition on the risk recognition measures. We found a significant effect of risk prominence on two of the risk recognition measures, and a significant interaction on a third measure. Compared with participants in the low-risk prominence condition, participants in the high-risk prominence condition were more likely to recognize the risk of fracture presented in the video and the risk of special liver tests that was alluded to in the video but presented only in the website text (F_{1,860} = 6.54, P = .01, d = .17 and F_{1,860} = 7.88, P = .01, d = .19, respectively). There was a significant interaction for the nursing warning presented only in the website text (F_{1,860} = 10.38, P < .001, d = .22). In the mechanism of action conditions, 83.8% (standard error [SE] 3.0) of participants in the high-risk prominence condition and 75.2% (SE 3.6) in the low-risk prominence condition recognized the nursing warning; however, this was reversed in the testimonial conditions (high-risk prominence = 64.1% [SE 5.2] and low-risk prominence = 83.1% [SE 3.6]).

Table 2. Weighted percentages and means (standard errors) by risk prominence.

| Risk retention variables                  | AR^a sample |            | HBP^b sample |            |
|------------------------------------------|-------------|------------|--------------|------------|
|                                          | Low-risk    | High-risk  | Low-risk     | High-risk  |
|                                          | prominence  | prominence | prominence   | prominence |
|                                          | (n=426)     | (n=35)     | (n=419)      | (n=404)    |
| Risk recall, mean (SE)                   | 1.80 (0.12)^d | 2.13 (0.11) | 1.02 (0.09)  | 1.12 (0.08) |
| Risk recognition: video, % (SE)          |             |            |              |            |
| AR fracture risk and HBP diarrhea risk    | 77.5 (3.4)^d | 88.4 (2.5)  | 66.6 (3.7)^d | 86.9 (2.7) |
| AR nausea risk and HBP salt intake warning| 77.5 (3.2)  | 77.2 (3.1)  | 68.0 (3.3)   | 71.1 (3.6) |
| Risk recognition: text, % (SE)           |             |            |              |            |
| AR liver warning and HBP fetal risk       | 65.4 (3.7)^d | 79.3 (3.2)  | 69.3 (3.5)^d | 58.7 (3.7) |
| AR nursing warning and HBP angioedema warning| 79.1 (3.0) | 73.9 (3.1)  | 63.0 (3.9)^d | 49.0 (3.7) |
| Benefit recall, % (SE)                    | 44.2 (3.9)  | 38.3 (3.5)  | 70.1 (3.6)   | 62.3 (3.7) |
| Benefit recognition, % (SE)               | 85.6 (2.7)  | 82.7 (2.8)  | 88.4 (2.7)   | 80.3 (3.3) |

^aAR: acid reflux.
^bHBP: high blood pressure.
^cRisk recall: 0-6 correct in the AR sample and 0-7 in the HBP sample.
^dSignificantly different from the high-risk prominence condition, P < .05.
On comparing the video type conditions with the control condition on risk recall and risk recognition, we found effects for one risk recognition measure. Compared with participants in the mechanism of action and testimonial conditions, participants in the control condition were more likely to recognize the nausea risk presented in the video ($F_{1,822}=17.22$, $P<.001$, $d=.29$). However, they were less likely to recognize the fetal and angioedema risks presented only in the website text ($F_{1,822}=4.30$, $P=.04$, $d=.14$ and $F_{1,822}=6.39$, $P=.01$, $d=.18$, respectively).

The risk prominence and video type conditions did not significantly differ on the risk recognition measure regarding the nausea risk presented in the video ($P>.05$).

### High Blood Pressure

We tested the effect of risk prominence and video type condition on risk recall. We found that participants in the mechanism of action condition recalled more risks compared with participants in the testimonial condition ($F_{1,1054}=12.33$, $P<.001$, $d=.22$).

The risk prominence and video type condition did not significantly differ on the risk recognition measure regarding the salt intake risk presented in the video ($P>.05$).

#### Retention of Drug Benefit Information

**Acid Reflux**

We tested the effect of risk prominence and video type condition on benefit recall and benefit recognition. We found no significant effects for benefit recall ($P>.05$). We found significant effects for benefit recognition when we compared the video type conditions. Specifically, participants in the testimonial and control conditions were more likely to recognize the drug’s benefit compared with participants in the mechanism of action conditions ($F_{1,860}=15.22$, $P<.001$, $d=.26$ and $F_{1,1054}=11.74$, $P=.001$, $d=.21$, respectively).

#### High Blood Pressure

We tested the effect of risk prominence and video type conditions on benefit recall and benefit recognition. We found significant effects for benefit recall and benefit recognition when we compared the video type conditions. Participants in the mechanism of action condition were more likely to recall the drug’s benefit compared with participants in the testimonial and control conditions ($F_{1,822}=5.27$, $P=.02$, $d=.16$ and $F_{1,1054}=7.50$, $P=.01$, $d=.17$, respectively). They were also more likely to recognize the drug’s benefit compared with participants in the testimonial condition ($F_{1,822}=6.01$, $P=.01$, $d=.17$).

---

### Table 3. Weighted percentages and means (standard errors) by video type condition.

| Risk retention variables | AR$^a$ sample | HBP$^b$ sample |
|--------------------------|---------------|----------------|
|                          | AR mechanism of action (n=430) | HBP mechanism of action (n=412) |
| Risk recall$^c$, mean (SE) | 1.90 (0.11) | 1.20$^d$ (0.09) |
| Risk recognition: video, % (SE) | | |
| AR fracture risk and HBP diarrhea risk | 83.7 (3.0) | 79.1 (3.0) |
| AR nausea risk and HBP salt intake warning | 75.0 (3.4) | 69.8 (3.3) |
| Risk recognition: text, % (SE) | | |
| AR liver warning and HBP fetal risk | 68.6 (3.7) | 63.8 (3.5) |
| AR nursing warning and HBP angioedema warning | 79.5 (2.8)$^e$ | 61.2 (3.7) |
| Benefit recall, % (SE) | 41.7 (3.6) | 72.1 (3.3)$^d,e$ |
| Benefit recognition, % (SE) | 77.4 (3.1)$^d,e$ | 89.8$^d$ (2.3) |

$^a$AR: acid reflux.
$^b$HBP: high blood pressure.
$^c$Risk recall: 0-6 correct in the AR sample and 0-7 in the HBP sample.
$^d$Significantly different from the testimonial condition, $P<.05$.
$^e$Significantly different from the control condition; Bonferroni-adjusted for two comparisons with the control condition, $P<.025$. 

---

http://www.jmir.org/2018/1/e13/
Table 4. Weighted means (standard errors) by risk prominence.

| Dependent variables                                      | Acid reflux sample, mean (SE) | High blood pressure sample, mean (SE) |
|----------------------------------------------------------|------------------------------|--------------------------------------|
|                                                          | Low-risk prominence          | High-risk prominence                | Low-risk prominence | High-risk prominence |
| Perceived drug risk                                      |                              |                                      |                      |
| Likelihood a                                            | 33.11 (1.92)                 | 31.93 (1.69)                         | 33.34 (1.83)         | 37.29 (1.89)         |
| Magnitude b                                             | 3.46 (0.09)                  | 3.76 (0.08)                         | 3.75 (0.09)          | 3.73 (0.08)          |
| Perceived drug efficacy                                 |                              |                                      |                      |
| Likelihood a                                            | 70.66 (1.50)                 | 71.43 (1.47)                         | 64.48 (1.80)         | 65.25 (1.69)         |
| Magnitude d                                             | 4.84 (0.08)                  | 4.95 (0.07)                         | 4.79 (0.08)          | 4.52 (0.09)          |
| Perceived balance of drug benefits and risks e           | 4.51 (0.11)                  | 4.42 (0.11)                         | 4.49 (0.08)          | 4.33 (0.10)          |
| Intention f                                             |                              |                                      |                      |
| Physician interaction                                   | 2.88 (0.09)                  | 2.74 (0.09)                         | 2.55 (0.10)          | 2.29 (0.10)          |
| Search on the Internet                                  | 2.50 (0.09)                  | 2.39 (0.08)                         | 2.38 (0.10)          | 2.12 (0.09)          |
| Website skepticism f                                     | 3.49 (0.09)                  | 3.45 (0.08)                         | 3.77 (0.08)          | 3.75 (0.10)          |
| Perceived balance of website benefit and risk information h | 5.16 (0.10)                  | 4.72 (0.10)                         | 5.14 (0.10)          | 4.78 (0.10)          |

aPerceived drug risk and efficacy likelihood: 0-100 people. Although transformations of perceived drug risk and efficacy likelihood were used in analyses, the untransformed weighted means are presented here for the ease of interpretation.
bPerceived drug risk magnitude: 1 (not at all serious) to 6 (very serious).
cSignificantly different from the high-risk prominence condition, P<.05.
dPerceived drug efficacy magnitude: 1 (help a little) to 6 (help a lot).
ePerceived balance of drug benefits and risks: 1 (risks outweigh benefits) to 7 (benefits outweigh risks).
fIntention: 1 (very unlikely) to 5=very likely).
gWebsite skepticism: 1 (extremely unlikely) to 7 (extremely likely).
hPerceived balance of website benefit and risk information: 1 (more emphasis on risks) to 7 (more emphasis on benefits).

Perceived Drug Efficacy

**Acid Reflux**
We tested the effect of risk prominence and video type condition on the perceived drug efficacy measures. We found no significant effects for perceived drug efficacy likelihood or magnitude (P>.05; Tables 4 and 5).

**High Blood Pressure**
We tested the effect of risk prominence and video type condition on the perceived drug efficacy measures. We found no significant effects (P>.05).

Perceived Drug Risk

**Acid Reflux**
We tested the effect of risk prominence and video type condition on perceived drug likelihood and magnitude. For perceived drug magnitude, we found a significant effect when comparing video type conditions with the control condition and a significant effect of risk prominence. Participants in the control condition thought that the drug’s side effects and negative outcomes would be more serious compared with participants in the mechanism of action condition (F1,1048=7.47, P=.01, d=.17). In addition, participants in the high-risk prominence condition thought that the drug’s side effects and negative outcomes would be more serious compared with participants in the low-risk prominence condition (F1,841=6.40, P=.01, d=.17). We found no significant effects for perceived drug risk likelihood (P>.05).

**High Blood Pressure**
We tested the effect of risk prominence and video type condition on perceived drug likelihood and magnitude. We found no significant effects (P>.05).

Perceived Balance of Drug Benefits and Risks

**Acid Reflux**
We tested the effect of risk prominence and video type condition on perceived balance of drug benefits and risks. We found no significant effects (P>.05).
| Dependent variables                                      | Acid reflux sample, mean (SE) | High blood pressure sample, mean (SE) |
|----------------------------------------------------------|-------------------------------|--------------------------------------|
|                                                           | Mechanism of action | Testimonial | Control | Mechanism of action | Testimonial | Control |
| **Perceived drug risk**                                  |                               |            |         |                     |            |         |
| Likelihood^a                                             | 34.40 (1.95)              | 30.67 (1.62) | 36.08 (2.69) | 37.25 (1.90)              | 33.21 (1.78) | 35.98 (2.49) |
| Magnitude^b                                             | 3.52 (0.08)              | 3.70 (0.10) | 3.93 (0.13) | 3.72 (0.09)              | 3.76 (0.09) | 3.89 (0.12) |
| **Perceived drug efficacy**                              |                               |            |         |                     |            |         |
| Likelihood^a                                             | 72.38 (1.34)              | 69.70 (1.61) | 74.97 (2.09) | 66.48 (1.40)              | 63.20 (2.02) | 64.23 (1.98) |
| Magnitude^d                                             | 4.88 (0.07)              | 4.92 (0.08) | 5.02 (0.10) | 4.71 (0.08)              | 4.60 (0.09) | 4.50 (0.09) |
| Perceived balance of drug benefits and risks^e            | 4.50 (0.10)              | 4.43 (0.12) | 4.62 (0.15) | 4.57 (0.08)              | 4.25 (0.10) | 4.37 (0.12) |
| **Intention^g**                                          |                               |            |         |                     |            |         |
| Physician interaction                                   | 2.81 (0.08)              | 2.81 (0.10) | 2.83 (0.13) | 2.48 (0.10)              | 2.37 (0.10) | 2.12 (0.12) |
| Search on the Internet                                  | 2.39 (0.08)              | 2.48 (0.09) | 2.50 (0.12) | 2.36 (0.10)              | 2.14 (0.09) | 2.11 (0.11) |
| Website skepticism^h                                     | 3.35 (0.07)              | 3.58 (0.09) | 3.24 (0.12) | 3.70 (0.09)              | 3.82 (0.09) | 3.69 (0.11) |
| Perceived balance of website benefit and risk information | 5.05 (0.09)              | 4.83 (0.11) | 4.69 (0.16) | 5.07 (0.10)              | 4.85 (0.10) | 4.27 (0.16) |

^aPerceived drug risk and efficacy likelihood: 0-100 people. Although transformations of perceived drug risk and efficacy likelihood were used in analyses, the untransformed weighted means are presented here for ease of interpretation.

^bPerceived drug risk magnitude: 1 (not at all serious) to 6 (very serious).

^cSignificantly different from the control condition; Bonferroni-adjusted for two comparisons with the control condition, P<.025.

^dPerceived drug efficacy magnitude: 1 (help a little) to 6 (help a lot).

^ePerceived balance of drug benefits and risks: 1 (risks outweigh benefits) to 7 (benefits outweigh risks).

^fSignificantly different from the testimonial condition, P<.05.

^gIntentions: 1 (very unlikely) to 5 (very likely).

^hWebsite skepticism: 1 (extremely unlikely) to 7 (extremely likely).

^iPerceived balance of website benefit and risk information: 1 (more emphasis on risks) to 7 (more emphasis on benefits).

**High Blood Pressure**
We tested the effect of risk prominence and video type condition on the perceived balance of drug benefits and risks. We found a significant effect of video type condition. Participants in the mechanism of action condition thought that the benefits outweighed the risks compared with participants in the testimonial condition (F_{1,809}=6.25, P=.01, d=.18).

**Behavioral Intentions**
**Acid Reflux and High Blood Pressure**
We tested the effect of risk prominence and video type condition on physician interaction and Internet search intentions. In both the acid reflux and high blood pressure samples, we found no significant effects (P>.05).

**Website Skepticism**
**Acid Reflux**
We tested the effect of risk prominence and video type condition on website skepticism. We found a significant effect of video type condition and a significant interaction. Participants in the testimonial condition were more skeptical of the website compared with participants in the control and mechanism of action conditions (F_{1,1063}=5.47, P=.02, d=.14 and F_{1,856}=4.14, P=.04, d=.14, respectively). A significant interaction with risk prominence (F_{1,856}=4.63, P=.03) suggests that this was driven by the low-risk prominence conditions (testimonial, low-prominence condition mean=3.72, SE 0.12; mechanism of action video, low-prominence condition mean=3.25, SE 0.11; testimonial, high-prominence condition mean=3.44, SE 0.13; mechanism of action video, high-prominence condition mean=3.46, SE 0.10).

**High Blood Pressure**
We tested the effect of risk prominence and video type conditions on website skepticism. We found no significant effects (P>.05).

**Perceived Balance of Website Benefit and Risk Information**
**Acid Reflux**
We tested the effect of risk prominence and video type condition on the perceived balance of website benefit and risk information. The effect of risk prominence was significant; participants in the low-risk prominence condition thought that the website placed more emphasis on benefits compared with participants...
in the high-risk prominence condition \((F_{1,857}=9.50, P=.002, d=.21)\).

**High Blood Pressure**

We tested the effect of risk prominence and video type condition on the perceived balance of website benefit and risk information. We found significant effects when comparing video type conditions with the control condition, and a significant effect of risk prominence. Participants in the mechanism of action and testimonial conditions thought that the website placed more emphasis on benefits compared with participants in the control condition \((F_{1,1037}=17.56, P<.001, d=.26\) and \(F_{1,1037}=9.35, P=.002, d=.19\), respectively). Participants in the low-risk prominence condition thought that the website placed more emphasis on benefits compared with participants in the high-risk prominence condition \((F_{1,809}=6.17, P=.01, d=.17)\).

**Discussion**

**Principal Findings**

This study investigated how videos embedded on branded prescription drug websites influence consumers’ knowledge, perceptions, and intentions. We tested websites with no video, with a testimonial, and with an informational video describing the drug’s mechanism of action. Within the testimonial and mechanism of action videos, we manipulated the prominence of risk information, with some risk information included, or not included, in the videos (with risk information always present in the text of the website). The results of this study suggest that embedded videos can affect consumers’ knowledge of drug information but are less likely to affect perceptions and intentions.

We found that including risk information in videos increased participants’ recognition of the risks presented in the videos. However, in some cases, including risk information in videos decreased participants’ recognition of the risks not presented in the videos (ie, risks presented in text only). The Communication-Human Information Processing Model states that for risk information to be understood, individuals must first switch their attention to the information and then maintain their attention on the information [35,36]. The videos may capture and maintain their attention; therefore, when videos are presented on websites, the inclusion of risks in the videos can increase the retention of some of those risks. At the same time, it may decrease the retention of risks not mentioned in the video by preventing individuals from switching and maintaining their attention on the text. Participants may assume that all risks are included in the video, and therefore, they may not read the risk information provided only in the website’s text.

Including risks in the video did not affect participants’ retention of the drug’s main benefit, although in the high blood pressure sample, it did decrease the perceived magnitude of drug efficacy. In addition, we found that not including risk information in the videos shifted participants’ views of the website, causing them to believe that the website placed more emphasis on benefits. In most cases, however, this did not translate into increased skepticism of the website; only participants in the acid reflux sample who saw the testimonial without risk information reported more skepticism. These findings suggest that if videos are used, the inclusion of risk information in videos can increase consumers’ knowledge of the risks while not diminishing consumers’ knowledge of the drug’s benefit or making them more skeptical.

We found that the videos had no effect on intentions and a limited effect on risk perceptions; in the acid reflux sample only, including risk information in the videos increased the perceived magnitude of the drug’s risks. Quantifying or personalizing the risks in testimonials may be necessary to change perceptions. These findings are also consistent with previous research demonstrating that consumers consider numerous sources of information about prescription drugs—particularly, health care providers—and that their perceptions of and intentions about specific medications are influenced by multiple factors, including their personal health history, satisfaction with current treatment, and knowledge of others’ experiences with the drugs [37-43]. Consequently, Web videos promoting a prescription drug may not be powerful or persuasive enough to shift individuals’ perceptions and intentions unless they are part of a larger marketing campaign or align with a health care provider’s recommendation to take a medication.

The study samples consisted of individuals who had been diagnosed with one of two health conditions—acid reflux and high blood pressure. Across medical conditions, we saw a similar pattern of effects for risk prominence, such that risk prominence affected risk retention but had little or no effect on benefit retention and perceptions. This provides some confidence that these results would generalize across different medical conditions and different website and video executions. However, the effects of video type condition were not consistent across medical conditions. The two video styles examined in this study—testimonials and mechanism of action videos—were not entirely equivalent, and the executions differed across medical conditions. To be realistic and to mirror actual content on branded drug websites, the videos contained different benefit information. The mechanism of action videos focused on how each fictitious drug worked; the testimonials presented an individual patient’s experience benefiting from the fictitious drug. This distinction means that differences between testimonial and mechanism of action video type conditions in the study’s findings could be caused by multiple factors, such as video style (eg, live action vs animated), video content, or even video duration. The benefit retention results reflect this; in the acid reflux sample, the mechanism of action video decreased the retention of the drug's benefits, whereas it increased retention in the high blood pressure sample. Future research should standardize content within testimonials and mechanism of action videos to determine whether differences are attributable to visuals or content. This would provide a less realistic, but more controlled, setting in which these concepts can be tested.

**Limitations**

This study was a controlled experiment with realistic stimuli, large sample sizes, and high statistical power. Nevertheless, the study has several limitations that should be considered when interpreting the findings. First, the study samples were limited to individuals with household broadband Internet access and,
thus, may contain a higher proportion of white, older, and more educated individuals than the US adult population. The study was also limited to participants with two illness conditions and did not include individuals without health issues. One avenue for future research is to test these concepts in a different sample. For instance, future research could focus on individuals actively seeking prescription treatments (eg, newly diagnosed and dissatisfied with current treatment). Future research should also examine whether key differences between these two illness conditions (eg, symptomatic vs asymptomatic, many nonprescription treatment options vs few nonprescription treatment options) explain why certain effects were present in only one population.

Individuals may be passively exposed to television and print DTC advertising, whereas individuals who visit DTC websites may be actively seeking information about treatments. Thus, participants in our study may have had less interest in and paid less attention to the study DTC website compared with individuals actively seeking information on the Internet. Conducting future research with individuals actively seeking prescription treatments would partially address this limitation as well.

Conclusions
Our results reflect the caution in using testimonials urged by Elwyn and colleagues [27]. Including a video on a prescription drug website can affect website credibility (for instance, by increasing skepticism and changing the perceived balance of information on the website). It can also enhance or detract from consumers’ knowledge of the drug’s benefits and risks. When videos are used on prescription drug websites, the inclusion of risk information in the videos can lead to greater knowledge of the product’s important risk information. Thus, “fair balance” may be enhanced by including risk information in website videos.

Acknowledgments
This study was funded by a contract from the US Food and Drug Administration, Office of Prescription Drug Promotion. The authors would like to acknowledge Kayla Gray, Scott Boggs, Elizabeth Robbins, Maria Ashbaugh, Cliff Haac, and John Bollenbacher (RTI International) for their help with developing the stimuli and Rebecca Moultrie (RTI International) and Bridget Kelly (RTI International) for their assistance in creating questionnaires and collecting data. The authors would also like to thank Sarah Kandefer, Grier Page, Annette Green, and Paul Mosquin (RTI International) for their help with the analysis.

Conflicts of Interest
None declared.

References
1. Avery RJ, Eisenberg MD, Simon KI. The impact of direct-to-consumer television and magazine advertising on antidepressant use. J Health Econ 2012 Sep;31(5):705-718. [doi: 10.1016/j.jhealeco.2012.05.002] [Medline: 22835472]
2. Daubresse M, Hutfless S, Kim Y, Kornfield R, Qato DM, Huang J, et al. Effect of direct-to-consumer advertising on asthma medication sales and healthcare use. Am J Respir Crit Care Med 2015 Jul 01;192(1):40-46 [FREE Full text] [doi: 10.1164/rcrm.201409-1585OC] [Medline: 25879303]
3. Government Accountability Office. Prescription drugs: Improvements needed in FDA’s oversight of direct-to-consumer advertising. Washington, DC: US Government Accountability Office; 2006.
4. Kim Y, Kornfield R, Shi Y, Vera L, Daubresse M, Alexander GC, et al. Effects of televised direct-to-consumer advertising for varenicline on prescription dispensing in the United States, 2006-2009. Nicotine Tob Res 2016 May;18(5):1180-1187. [doi: 10.1093/ntr/ntv198] [Medline: 26385926]
5. Layton JB, Kim Y, Alexander GC, Emery SL. Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013. JAMA 2017 Dec 21;317(11):1159-1166 [FREE Full text] [doi: 10.1001/jama.2016.21041] [Medline: 28324090]
6. Niederdeppe J, Byrne S, Avery RJ, Cantor J. Direct-to-consumer television advertising exposure, diagnosis with high cholesterol, and statin use. J Gen Intern Med 2013 Jul;28(7):886-893 [FREE Full text] [doi: 10.1007/s11606-013-2379-3] [Medline: 23463454]
7. Frosch D, Grande D. Direct-to-consumer advertising of prescription drugs. LDI Issue Brief 2010;15(3):1-4. [Medline: 20469541]
8. Grenard JL, Uy V, Pagán JA, Frosch DL. Seniors’ perceptions of prescription drug advertisements: a pilot study of the potential impact on informed decision making. Patient Educ Couns 2011 Oct;85(1):79-84 [FREE Full text] [doi: 10.1016/j.pec.2010.10.008] [Medline: 21044826]
9. Mintzes B. Advertising of prescription-only medicines to the public: does evidence of benefit counterbalance harm? Annu Rev Public Health 2012 Apr;33:259-277. [doi: 10.1146/annurev-publhealth-031811-124540] [Medline: 22429162]
10. Mackey TK, Cuomo RE, Liang BA. The rise of digital direct-to-consumer advertising?: comparison of direct-to-consumer advertising expenditure trends from publicly available data sources and global policy implications. BMC Health Serv Res 2015 Jun 19;15:236 [FREE Full text] [doi: 10.1186/s12913-015-0885-1] [Medline: 26084705]
11. Sullivan HW, Aikin KJ, Chung-Davies E, Wade M. Prescription drug promotion from 2001-2014: data from the U.S. food and drug administration. PLoS One 2016;11(5):e0155035 [FREE Full text] [doi: 10.1371/journal.pone.0155035] [Medline: 27149513]
12. Kornfield R, Donohue J, Berndt ER, Alexander GC. Promotion of prescription drugs to consumers and providers, 2001-2010. PLoS One 2013;8(3):e55504 [FREE Full text] [doi: 10.1371/journal.pone.005504] [Medline: 23469165]
13. Dupuis FM. The effects of the internet on pharmaceutical consumers and providers. Dis Manag Health Out 2002;10(11):679-691. [doi: 10.2165/00115677-200210110-00002]
14. Sheehan KB. In poor health: an assessment of privacy policies at direct-to-consumer web sites. J Public Policy Mark 2005 Sep;24(2):273-283. [doi: 10.1509/jppm.2005.24.2.2723]
15. Griffiths KM, Christensen H, Evans K. Pharmaceutical company websites as sources of information for consumers. Dis Manag Health Out 2002;10(4):205-214. [doi: 10.2165/00115677-200210040-00001]
16. Ledford CJ. Content analysis of internet marketing strategies: how pharmaceutical companies communicate about contraceptives with consumers online. Soc Mar Q 2009 Jul 15;15(sup1):55-71. [doi: 10.1080/1524009090318308]
17. Macias W, Lewis LS. A content analysis of direct-to-consumer (DTC) prescription drug web sites. J Advertising 2003 Dec;32(4):43-56. [doi: 10.1080/0091933031063147]
18. Pashupati K. Beavers, bubbles, bees, and moths. JAR 2009 Sep 01;49(3):373-393. [doi: 10.2501/S002184990900473]
19. Frosch DL, Krueger PM, Hornik RC, Cronholm PF, Barg FK. Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising. Ann Fam Med 2007;5(1):6-13 [FREE Full text] [doi: 10.1370/afm.611] [Medline: 17261859]
20. Logan K. And now a word from our sponsor: do consumers perceive advertising on traditional television and online streaming video differently? J Mark Commun 2012;19(4):258-276 [FREE Full text] [doi: 10.1080/13527266.2011.631568]
21. Boucheix J, Schneider E. Static and animated presentations in learning dynamic mechanical systems. Learn Instr 2009 Apr;19(2):112-127. [doi: 10.1016/j.learninstruc.2008.03.004]
22. Höfﬂer TN, Leutner D. Instructional animation versus static pictures: a meta-analysis. Learn Instr 2007 Dec;17(6):722-738. [doi: 10.1016/j.learninstruc.2007.09.013]
23. Mevissen FEF, Meertens RM, Ruiter RAC, Feenstra H, Schaalma HP. HIV/STI risk communication: the effects of scenario-based risk information and frequency-based risk information on perceived susceptibility to chlamydia and HIV. J Health Psychol 2009 Jan;14(1):78-87. [doi: 10.1177/1359105308097948] [Medline: 19129340]
24. Nan X, Dahlstrom MF, Richards A, Rangarajan S. Influence of evidence type and narrative type on HPV risk perception and intention to obtain the HPV vaccine. Health Commun 2015;30(3):301-308. [doi: 10.1080/10410236.2014.888629] [Medline: 25061715]
25. Pot M, van Keulen HM, Paulussen TWGM, Otten W, Ruiter RA. Statistical variation versus narrative risk information: implications for future communication about HPV vaccination. European Health Psychologist 2014;16:579.
26. Trevena LJ, Zikmund-Fisher BJ, Edwards A, Gaismaier W, Galesic M, Han PK, et al. Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak 2013;13 Suppl 2:S7 [FREE Full text] [doi: 10.1186/1472-6947-13-S2-S7] [Medline: 24625327]
27. Elwyn G, O’Connor A, Stacey D, Volk R, Edwards A, Coulter A, et al. Developing a quality criteria framework for patient decision aid developers. BMC Med Inform Decis Mak 2006 Aug 26;6(Suppl 2):S7 [FREE Full text] [doi: 10.1186/bmj.38926.629329.AE] [Medline: 16908462]
28. Lewalter D. Cognitive strategies for learning from static and dynamic visuals. Learn Instr 2009 Apr;19(2):112-127. [doi: 10.1016/j.learninstruc.2008.03.004]
29. US Food and Drug Administration. 2016. Prescription-drug advertisements 21 CFR 202.1 URL: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfscript/CFRSearch.cfm?frr=202 [JWebCite Cache ID 6wpZDT1pX]
30. U.S. Food and Drug Administration. FDA. 2014. Guidance for Industry: internet/social media platforms with character space limitations—presenting risk and benefit information for prescription drugs and medical devices URL: https://www.fda.gov/downloads/drugs/guidances/ucm401087.pdf [accessed 2017-12-28] [WebCite Cache ID 6w2olFLB]
31. Hoy MG, Park JS. Principles in action: an examination of food and drug administration letters involving violent internet prescription promotions from 1997 to 2012. J Public Policy Mark 2014 Nov;33(2):127-142. [doi: 10.1509/jppm.12.097]
32. Mintzes B. The tip of the iceberg of misleading online advertising comment on “trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of FDA warning letters”. Int J Health Policy Manag 2016 Feb 18;5(5):329-331. [doi: 10.15171/ijhpm.2016.19]
33. Southwell BG, Rupert DJ. future challenges and opportunities in online prescription drug promotion research comment on “trouble spots in online direct-to-consumer prescription drug promotion: a content analysis of FDA warning letters”. Int J Health Policy Manag 2016 Jan;5(3):211-213 [FREE Full text] [doi: 10.15171/ijhpm.2016.05] [Medline: 26927597]
34. U.S. Food and Drug Administration. FDA. 2014. Public hearing on promotion of FDA-regulated medical products using the internet and social media tools URL: https://www.fda.gov/AboutFDA/centers/offices/officeofmedicalproductsandtobacco/CDER/ucm184250.htm [accessed 2017-12-19] [WebCite Cache ID 6wpYOLpb]
35. Conzola V, Wogalter M. A communication-human information processing (C-HIP) approach to warning effectiveness in the workplace. J Risk Res 2001;4(4):309-322. [doi: 10.1080/1366987011006271]
36. Wogalter M. Communication-human information processing (C-HIP) model. In: Handbook of Warnings. Mahwah, NJ: Lawrence Erlbaum Associates; 2006:51-61.
37. Chen C, Wu J, Yen M, Chen Z. A model of medication-taking behavior in elderly individuals with chronic disease. J Cardiovasc Nurs 2007;22(5):359-365. [doi: 10.1097/01.JCN.0000287029.87746.58] [Medline: 17724416]
38. DeLorme DE, Hub J, Reid LN. Seniors' perceptions of prescription drug information sources. Int J Pharm Healthc Mark 2007 Jul 03;1(2):107-127. [doi: 10.1108/17506120710762979]
39. Doucette WR, Schommer JC. Consumer preferences for drug information after direct-to-consumer advertising. Drug Information Journal 1998 Jan 01;32(4):1081-1088. [doi: 10.1177/009286159803200428]
40. Gregory R, Peters E, Slocie P. Making decisions about prescription drugs: a study of doctor–patient communication. Health Risk Soc 2011 Jun;13(4):347-371. [doi: 10.1080/13698575.2011.575455]
41. Kim WJ, King KW. Product category effects on external search for prescription and nonprescription drugs. J Advert 2009 Apr;38(1):5-20. [doi: 10.2753/JOA0091-3367380101]
42. Lau DT, Briesacher BA, Mercalado ND, Halpern L, Osterberg EC, Jarzebowski M, et al. Older patients’ perceptions of medication importance and worth: an exploratory pilot study. Drugs Aging 2008;25(12):1061-1075 [FREE Full text] [Medline: 19021304]
43. Makoul G, Arntson P, Schofield T. Health promotion in primary care: physician-patient communication and decision making about prescription medications. Soc Sci Med 1995 Nov;41(9):1241-1254. [Medline: 8545677]

Abbreviations

ANOVA: analysis of variance  
DTC: direct-to-consumer  
FDA: Food and Drug Administration

©Helen W Sullivan, Amie C O'Donoghue, Jennifer Gard Read, Jacqueline B Amoozegar, Kathryn J Aikin, Douglas J Rupert. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 23.01.2018. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on http://www.jmir.org/, as well as this copyright and license information must be included.